Cleveland Clinic cardiologist Dr. A. Michael Lincoff is part of a new nine-member medical advisory board at Regado Biosciences, a New Jersey company developing quickly reversible anti-clotting drugs.
Lincoff is the director of the Clinic’s Coordinating Center for Clinical Research and its Center for Clinical Research. He is also vice chairman of both the Lerner Research Institute and the department of cardiovascular medicine.
The medical board will advise Regado on its clinical programs and guide the commercialization of its primary product: the REG1 anticoagulation system, which the company says can help with heart problems including acute coronary syndrome. Regado also hopes it can replace standard heparin therapy during some balloon angioplasties and stentings.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Regado is preparing a Phase IIb study for later this year. Its investors include Domain Associates, Quaker BioVentures, Aurora Funds and Caxton Advantage Life Sciences Fund.